STOCK TITAN
  1. Home
  2. News
  3. CRSP

CRISPR Therapeutics AG - CRSP STOCK NEWS

Welcome to our dedicated news page for CRISPR Therapeutics (Ticker: CRSP), a resource for investors and traders seeking the latest updates and insights on CRISPR Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CRISPR Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CRISPR Therapeutics's position in the market.

News
CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
CRISPR Therapeutics to present at Needham Virtual Healthcare Conference on April 10, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
conferences
-
News
CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
Rhea-AI Summary
CRISPR Therapeutics announces an oral presentation at the ASGCT 2024 Annual Meeting on the Development of an In Vivo Non-Viral Ocular Editing Platform for Glaucoma treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.03%
Tags
conferences
-
News
CRISPR Therapeutics Proposes New Appointment to the Board of Directors
Rhea-AI Summary
CRISPR Therapeutics (CRSP) announces the proposal to elect Christian Rommel, Ph.D., to its Board of Directors, bringing valuable experience in drug innovation and development. Dr. Rommel's expertise is expected to enhance CRISPR's platform and pipeline for creating gene-based medicines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
management
News
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
CRISPR Therapeutics achieves significant milestones in gene-based medicines with multiple clinical trials ongoing and a strengthened balance sheet through a $280 million offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.67%
Tags
earnings
-
News
CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit
Rhea-AI Summary
CRISPR Therapeutics (CRSP) to present at Citi 2024 Virtual Oncology Leadership Summit, offering a live webcast and replay option for investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.88%
Tags
conferences
-
News
CRISPR Therapeutics Announces $280 Million Registered Direct Offering
Rhea-AI Summary
CRISPR Therapeutics (CRSP) secures $280 million investment to advance clinical trials and gene writing programs, strengthening balance sheet with over $2.1 billion in pro forma cash.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.79%
Tags
offering
News
European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)
Rhea-AI Summary
CRISPR Therapeutics receives conditional marketing authorization from the European Commission for CASGEVY, a gene-edited therapy for severe sickle cell disease and transfusion-dependent beta thalassemia. Over 8,000 eligible patients in the EU may benefit from this approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.79%
Tags
none
-
News
CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia
Rhea-AI Summary
The U.S. FDA has approved CASGEVY, a CRISPR/Cas9 gene-edited cell therapy, for the treatment of transfusion-dependent beta thalassemia in patients 12 years and older. CRISPR Therapeutics, the biopharmaceutical company behind the treatment, is working with Vertex Pharmaceuticals to establish a network of treatment centers throughout the U.S. to offer CASGEVY to eligible patients. This approval reflects the power and versatility of the CRISPR platform to bring potentially curative treatment options to patients suffering from devastating diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.05%
Tags
none
-
News
CRISPR Therapeutics Highlights Strategic Priorities and 2024 Outlook
Rhea-AI Summary
CRISPR Therapeutics (CRSP) highlights 2024 outlook, strategic priorities, and recent achievements, including the first-ever approval of a CRISPR-based gene-editing therapy and entering the clinic with in vivo therapies. The company plans to expand its pipeline, drive clinical trials, and innovate on its platform with next-generation gene editing and delivery technologies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.33%
Tags
none
News
CRISPR Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
CRISPR Therapeutics (CRSP) to present at 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.3%
Tags
conferences
Stock CRSP logo
CRISPR Therapeutics AG

Nasdaq:CRSP

CRSP Rankings

#1211 Ranked by Market Cap
#3655 Ranked by Stock Gains
N/A Ranked by Dividends

CRSP Stock Data

5.15B
78.84M
1.35%
65.69%
18.38%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Switzerland
Zug

About CRSP

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.